(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 18 July 2002 (18.07.2002)

PCT

(10) International Publication Number WO 02/055593 A1

- (51) International Patent Classification⁷: C08J 7/04, 7/12, 7/18, C12N 11/08, Λ61L 27/34, 29/08, 31/10
- (21) International Application Number: PCT/EP02/00386
- (22) International Filing Date: 16 January 2002 (16.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

0101126.1 16 January 2001 (16.01.2001) GE

- (71) Applicant (for all designated States except US): CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE S.A. [CH/CH]; Jaquet-Droz 1, CH-2007 Neuchâtel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SIGRIST, Hans [CH/CH]; Im Holz 91, CH-3309 Kernelried (CH). LIN-DER, Vincent [CH/CH]; Kauffmannweg 4, CH-6003 Luzern (CH).
- (74) Agent: GOODMAN, Simon, John, Nye; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.





(54) Title: SURFACE PASSIVATION OF ORGANIC POLYMERS AND ELASTOMERS

(57) Abstract: Surface treatment of organic polymer materials and material surfaces with oligo- or polysaccharide as passivation agent for deliberate alteration of the sorption properties, the diffusion barrier function, lubricative wetting and/or biocompatibility of organic polymers, is described. The passivating agent is derivatized with chemical entities that allow tight adsorption and/or covalent binding of the passivating agent to organic polymers or elastomer surfaces. The passivating agent may be derivatized with a primary functional group to allow covalent surface passivation by photo- or thermal activation of the derivative. The passivating agent may comprise one or more secondary functional groups that allow covalent binding of probe molecules and receptors to the passivated surface. The surface treatment improves the biocompatibility of medical devices and the performance of bioanalytical systems. Its application for heterogeneous affinity based assays, biosensor analysis platforms, microcontact printing, and lubrication of medical devices is described. Devices comprising surface passivated PDMS organic polymer are also described.

- 1 -

Surface Passivation of Organic Polymers and Elastomers

Prior art

5

10

15

20

25

30

It is known that the properties of polymer surfaces may be modulated by integrating polar or charged components or monomeric precursor analogues in the polymerization process. Post-polymerization surface treatments are equally established, e.g. plasma treatment followed by exposure to aqueous media renders organic polymers highly wettable, and surface silylation has been applied to introduce selectively reactive functionalities on organic polymer material surfaces. In a recent approach, PDMS (polydimethylsiloxane) microchannels were fabricated using replica molding techniques. Surface passivation was achieved by multimeric protein (Immunoglobulin M) adsorption or by theromochemical crosslinking of a capture protein (protein A) with glutaraldehyde. (E. Eteshola, D. Leckband, Sensors and Actuators B 72 (2001) 129-133).

The increasing use of binary or ternary composite polymers in bio-analytical and medical devices demands unifying surface modification processes that are indistinguishably applicable to different polymer chemistries. It is widely documented that C-H, C=C and O-H bonds - the most frequent chemical bonds in organic polymers and elastomers - are chemically reactive with generated carbenes and ketyl radicals. Such chemical intermediates can be generated locally by thermal or light activation. The reactivity of many organic polymers with e.g. photogenerated carbenes was shown using low molecular weight crosslinkers or photolabel derivatized macromolecules including proteins and nucleic acids.

Several patents and scientific research articles report on the advantageous properties of oligo- and polysaccharides

- 2 -

to adsorb and store water or aqueous media. When conjugated to material surfaces polysaccharides form biocompatible passivating layers leading to improved performance of bioanalytical systems. However, establishment of such passivating layers requires a specific substrate and a sequence of at least two surface chemical steps to attain the requested conjugate.

Summary of the Invention

5

10

20

The invention in its various aspects is defined in the appended independent claims, to which reference should now be made. Preferred or advantageous features of the invention are set out in dependent subclaims.

Thus, the invention may advantageously overcome the problems in the prior art discussed above.

15 In its various aspects, the invention relates to the treatment of material surfaces, in particular organic polymers and elastomers of natural or synthetic origin that require unique or particular surface properties for adequate device function. Although organic polymers are numerous with respect to their chemistry, complexity, physical properties, their mode of use and fields of application, there are restricted means to render them compatible with biological systems. In view of engineering of material surfaces for bioanalytical purposes, surface structuring with biomolecules, and 25 medical applications there is a need for adaptation of organic materials and composites for appropriate function when contacted with biological systems. This invention relates to material surface treatment that may advantageously result in a close mimic of biological 30 systems: the generic approach of in situ generation of chemically reactive species in conjunction with the

- 3 -

passivating properties of polysaccharide may advantageously render novel properties to materials and may thus improve the efficiency of biocompatible devices.

The surfaces of solid organic polymers and elastomers are prone to physical adsorption and bi-directional diffusion of low molecular weight molecules. Diffusive sorption and release processes, as well as adsorptive binding properties of polymeric materials may advantageously be drastically suppressed by treatment of the polymer surfaces with oligo- or polysaccharides. Surface passivation by covalent or adsorptive thin-film coating may be attained by depositing and subsequent immobilization of biopolymers onto organic polymer or elastomer surfaces. Preferably, the passivating material is covalently bonded to the organic material yielding biocompatible surfaces as used in medical and analytical applications. With aryldiazirine or benzophenone derivatized oligo- or polysaccharides, covalent surface passivation may be attained by photo- or thermal activation of the polysaccharide derivative. passivation is exemplified by polydimethyldioxane microchannel treatment and application of the resulting systems for the detection of immunointeractions.

Description of the invention

10

15

20

The implementation of the invention will now be described, including description of several embodiments. Further details are also set out in the accompanying drawings. In a preferred embodiment, the invention may provide a surprisingly simple process to passivate organic polymer or elastomer surfaces. Thus, in tests, different types of polymer materials, individually or as composite material, were passivated by depositing carbene- or ketyl radical forming derivatives of polysaccharides in target surfaces. Derivatives of aminated polysaccharides such as

5

10

15

20

25

30

35

- 4 -

aminodextran or chitosan were prepared: the polysaccharides were thermochemically modified with benzophenone-4-isothiocyanate or isothiocyano-aryldiazirines, yielding benzophenone-dextran and benzophenone-chitosan, or aryldiazirine-dextran and aryldiazirine-chitosan, respectively. For covalent immobilization of these passivating agents, the reagents were thin-film deposited on the organic polymer surfaces and irradiated with activating light (wavelength: 350+20 nanometer, power: 10 microWatts per square centremetre, exposure time: 4 mintutes) or by heating to 80-115°C. Such surface treatment was effective for passivation of PDMS (polydimethylsiloxane) elastomers and polymers as for example, parylene, polystyrene, polyurethane, polycarbonate, polyvinylalcohol or polyvinyl difluoride. For analytical purposes, PDMS microchannels, forming parts of microfluidic systems, were passivated by either protein-mediated binding of dextran, or by direct immobilization of radical or carbene generating polysaccharides on PDMS.

Immobilization was feasible ex situ and in situ, in particular after the formation of functional microchannels. Both passivation procedures yielded surfaces that prevented diffusion of charged or polar low molecular weight chemicals into the PDMS matrix and suppressed the adsorption of proteins e.g. immunoqlobulins to analytically non-interfering levels. Furthermore, attachment of immunoreagents to passivated microfluidic channels or organic polymer surfaces via secondary functions (e.g. binding of antigens to photoimmobilized carboxy-dextran) generated immunoreactive polymer or elastomer surfaces. The described surface treatment may thus open new routes to fast and simply-implemented in situ passivation of structured organic materials, making them available for bioanalytical and biomedical applications.

- 5 **-**

Surface Bio-Passivation of Replicated µ-Fluidic Channels

Polydimethylsiloxane (PDMS) appeared recently as a material of choice for rapid and accurate replication of polymer-based microfluidic networks. However, due to its hydrophobicity, the surface strongly interacts with apolar analytes or species containing apolar domains, resulting in significant loss of sample to the substrate and, consequently, poor analytical performance. This contribution describes, with reference to the accompanying drawings and figure legends, the characterization of a native PDMS surface passivation treatment in microchannels.

Figures 1 and 2 show the behaviour of a fluorescent neutral marker in fused-silica/Pyrex;

Figure 3 shows schematically PDMS surface bio-passivation;
Figure 4 shows EO mobility in coated channels;
Figure 5 shows passivation and coating stability; and
Figure 6 shows biomolecule mobility in coated channels.

Figure Legends

20 Figure 1

30

5

10

Comparative capillary zone electrophoresis (CZE) runs of TMR-dextran and/or Caffeine.

Samples: in Na-acetate buffer 30mM pH=4.7 Working buffer: 30mM Na-acetate pH=4.7

Instrument: P/ACE 5510, UV detection at 214 nm Exp. Conditions: 6kV, 5sec injection time, 25°C Capillary: 20/27cm, ID=50 μm.

Tetramethylrhodamine labeled dextran 70 KDa (*TMR-dextran*) was shown to be neutral over the pH range 4.7 to 9.3. CZE runs of both caffeine (UV neutral marker) and TMR-dextran gave identical migration times.

~ 6 -

Figure 2

Boltzman fit for EO mobility measurements in Pyrex channels using TMR-dextran.

Pyrex channel, HF etched (20 µm deep)

Separation channel: total length 6cm, $70\mu m$ wide All buffers ionic strength I = 14mM

 $E = 650 \text{ Vcm}^{-1} \text{ (buffers pH 4.0 to 8.5)}$

 $E = 430 \text{ Vcm}^{-1} \text{ (buffers pH 8.95 to 10)}$

LIF detection (488 nm excitation)

10 Pinched injection

TMR-dextran was used as a fluorescent marker for EO mobility determination in Pyrex channels with a selection of acetate, phosphate and tetraborate buffers ranging from pH 4.0 to 10. Ionic strength remained constant. Results compare well with published data.

Figure 3

Schematic diagram of the coating used for passivation.

(1) Physisorption of biotin conjugate of IgG to PDMS; (2)
Neutravidin; (3) Biotin conjugate of dextran 10kDa.

20 Figure 4

15

30

Migration time of TMR-dextran in coated channels and calculated EO mobility.

Experimental conditions: running buffer (RB) 6.74 mM Tetraborate buffer pH 9.3; sample 50mM TMR-dextran in RB;

E=825 Vcm⁻¹; LIF detection (488nm excitation), pinched injection.

EO mobility was measured in microchannels by monitoring TMR-dextran detection times. Good reproducibility was obtained (RSD (n=10) <2%). However, EO mobility doubled within one month; this variation requires the use of an internal standard.

- 7 -

Figure 5

Adsorption of 20mM BODIPY-Digoxigenin in (a) uncoated and (b) coated channels (2 minutes incubation, hydrodynamic flow).

Channel preparation: replicas were obtained by moulding PDMS using a micromachined Si wafer as master. Drilled PDMS slabs were sealed against Pyrex wafers.

The three layer coating dramatically decreased adsorption for a variety of fluorescently labeled molecules and biopolymers, such as BODIPY-digoxigenin (MW 0.8kDa), TMR-dextran (MW 70kDa), FITC-human IgG (MW 150 kDa), and others.

The three layer coating appeared to be stable upon extensive exposure to buffers of neutral to basic pH, urine and human blood plasma. Short exposure to weak detergents (such as Tween 20) may be considered, but strong detergents (SDS) and very basic solutions (NaOH 0.1M) damage the coating rapidly.

Figure 6

15

35

Recorded peak compared with its Gaussian fit (zoom).

Experimental conditions: working buffer 7.92 mM Naphosphate buffer pH 7.0; sample 5µg/ml fluorescein mouse-IgG in diluted PBS; E=453 Vcm⁻¹; LIF detection (488nm excitation), pinched injection. Full run recorded at 5Hz, peak (zoom) at 500Hz.

Fluorescein-labeled mouse-IgG can be analyzed by CZE in a coated channel. The Gaussian peaks that are recorded indicate that no significant adsorption occurs. In uncoated channels, IgG adsorbs to the elastomer surface: it does not reach the detector.

Conclusion

The protein-based surface modification considerably decreases adsorption of fluorescently labelled low and high molecular weight substances. Moreover, the passivation layer is stable in buffers, as well as in

- 8 -

biological fluids such as serum or urine. Electroosmotic pumping in modified channels is also possible, making this an attractive surface treatment approach for many analytical applications.

- 9 -

Claims

5

10

1. Surface treatment of organic polymer materials and material surfaces with homo- or heteropolysaccharides as passivation agent for deliberate alteration of the sorption properties, the diffusion barrier function, lubricative wetting and/or biocompatibility of organic polymers, wherein the passivating agent is derivatized with chemical entities that allow tight adsorption and/or covalent binding of the passivating agent to organic polymers or elastomer surfaces.

- Surface treatment according to claim 1 where the organic polymer or elastomers are prepared by chemical precursor polymerization or materials of natural origin.
- 3. Surface treatment according to claim 1 or 2 where the organic polymer or elastomers are microstructured.
 - 4. Surface treatment according to claim 1, 2 or 3 wherein the passivating reagent is an oligo- or polysaccharide, preferably aminodextran or chitosan.
 - 5. Surface treatment according to any of claims 1 to 4 where the passivating agent is a polysaccharide containing a defined number of primary functional groups, fully or partially substituted with photoreagents such as benzophenone-4-isothiocyanate or with diazirino-aryl-isothiocyanates.
 - 6. Surface treatment according to any of claims 1 to 5, whereby the photoactivatable reagents are converted to reactive species by irradiation with light.

- 10 -

- 7. Surface treatment according to any of claims 1 to 5 wherein the photoactivatable reagents are converted to reactive species by heating to 80-115°C.
- 8. Surface treatment according to any of claims any of 1 to 7 where the passivating agent carries one or more secondary functional groups that allow covalent binding of probe molecules and receptors to passivated material surfaces.
- 9. Surface treatment according to claim 8 where the secondary functional group(s) are amino groups, carboxyl groups, maleimides, thiols, biotin, epoxides, chelating- or photoreactive entities.

5

15

20

25

30

- 10. A device in which the organic polymer is polydimethylsiloxane forming a replicated microchannel network on glass, quartz, silicium or organic polymers wherein channel surface passivation is attained by in situ or ex situ physisorption and subsequent light or temperature induced immobilization of aryldiazirine derivatized aminodextran.
- 11. A device in which the organic polymer is polydimethylsiloxane forming a replicated microchannel network on glass, quartz, silicium or organic polmer, whereby channel surface passivation is attained by in situ or ex situ physisorption of a protein-biotin conjugate and subsequent attachment of avidin analogues, the generated protein-based layer being additionally capped with biotin or biotinylated macromolecules including receptors, antibodies, nucleic acids, oligonucleotides, oligosaccharides or polysaccharides.

- 11 -


- 12. Application of the surface treatment according to any of claims 1 to 9 for heterogeneous affinity-based binding assays.
- 13. Application of the surface treatment according to any of claims 1 to 9 for molecular engineering of biosensor analysis platforms and fluidic devices to suppress physisorption and diffusion of molecules.

5

10

- 14. Application of the surface treatment according to any of claims 1 to 9 for the passivation of structured organic polymer surfaces used for microcontact printing.
 - 15. Application of the surface treatment of any of claims
 1 to 9 for the lubrication of medical devices
 including catheters and implants.
- 16. A biosensor analysis platform, a fluidic device, a structured organic polymer surface such as for use in microcontact printing, or a medical device, fabricated using the surface treatment method of any of claims 1 to 9.
- 20 17. A biosensor analysis platform, a fluidic device, a structured organic polymer surface such as for use in microcontact printing, or a medical device, incorporating a device as defined in claim 10 or 11.

Figure 1






Figure 3

(1)

(1)









Figure 5







INTERNATIONAL SEARCH REPORT

Interional Application No PCT/EP 02/00386

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C08J7/04 C08J7/12 A61L29/08 A61L31/10

C08J7/18

C12N11/08

A61L27/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

G. DOGGWI	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 16425 A (SIGRIST HANS ;KLINGLER DABRAL VIBHUTI (DE); DOLDER MAX (CH); WEGMU) 31 October 1991 (1991-10-31) page 1, paragraph 2 page 2, paragraphs 3,4 claims 1,5	1–17
X	US 5 714 360 A (SWAN DALE G ET AL) 3 February 1998 (1998-02-03) column 6, line 9 column 9, line 44-61 column 11, line 18-30	1-17
X	DE 197 24 869 A (HENKEL KGAA) 24 December 1998 (1998-12-24) claims 1-4 page 3, line 29/	1-17

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filling date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filling date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 24 May 2002	Date of mailing of the international search report 03/06/2002
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL- 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Natus, G

INTERNATIONAL SEARCH REPORT

Interplonal Application No PCT/EP 02/00386

		PCT/EP 02	/ 00380
	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 011, no. 307 (C-450), 7 October 1987 (1987-10-07) & JP 62 097611 A (MITSUBISHI RAYON CO LTD), 7 May 1987 (1987-05-07) abstract		1-17
A	DE 198 18 360 A (SUISSE ELECTRONIQUE MICROTECH ;KARLSRUHE FORSCHZENT (DE)) 4 November 1999 (1999-11-04) claims 1,2,6,7		1-17
A	WO 99 15917 A (NOVARTIS ERFIND VERWALT GMBH; NOVARTIS AG (CH)) 1 April 1999 (1999-04-01) claims 1,2		1-17
Α	US 4 326 532 A (HAMMAR WALTON J) 27 April 1982 (1982-04-27) claims 1,6		1-17

INTERNATIONAL SEARCH REPORT formation on patent family members

Intermional Application No						
PCT/EP	02/00386					

						02/00360
Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9116425	A	31-10-1991	AT WO DE DK EP	155524 9116425 59108783 484472 0484472	A1 D1 T3	15-08-1997 31-10-1991 21-08-1997 11-08-1997 13-05-1992
US 5714360	Α	03-02-1998	AU AU CA EP JP US WO	731249 7553196 2236588 0862624 2000500440 6077698 9716544	A A1 A1 T A	29-03-2001 22-05-1997 09-05-1997 09-09-1998 18-01-2000 20-06-2000 09-05-1997
DE 19724869	Α	24-12-1998	DE	19724869	A1	24-12-1998
JP 62097611	Α	07-05-1987	NONE			
DE 19818360	Α	04-11-1999	DE WO EP	19818360 9956119 1073895	A1	04-11-1999 04-11-1999 07-02-2001
WO 9915917	A	01-04-1999	AU WO EP JP TW US ZA	9627298 9915917 1023617 2001517731 396187 2001024697 9808670	A1 A1 T B A1	12-04-1999 01-04-1999 02-08-2000 09-10-2001 01-07-2000 27-09-2001 23-03-1999
US 4326532	Α	27-04-1982	AU CA DE EP JP JP MX	543926 7600981 1148468 3171034 0051354 1045373 1559151 57089868 155118	A A1 D1 A2 B C	09-05-1985 22-04-1982 21-06-1983 25-07-1985 12-05-1982 03-10-1989 16-05-1990 04-06-1982 29-01-1988